インデックス付き
- Jゲートを開く
- Genamics JournalSeek
- サイテファクター
- コスモスIF
- シマゴ
- ウルリッヒの定期刊行物ディレクトリ
- 電子ジャーナルライブラリ
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- 雑誌の抄録索引作成ディレクトリ
- OCLC-WorldCat
- プロクエスト召喚
- 学者の舵取り
- 道
- 仮想生物学図書館 (vifabio)
- パブロン
- ジュネーブ医学教育研究財団
- Google スカラー
このページをシェアする
ジャーナルチラシ
概要
CYP2D6*4 polymorphisms and breast cancer risk
D Surekha, K Sailaja, D Nageswara Rao, T Padma, D Raghunadharao, S Vishnupriya
CYP2D6 gene plays an important role in detoxification of many drugs and plays a crucial role in the metabolism of tamoxifen, used in endocrine therapy. In the present study, the heterozygous frequency IM (40.8%) was significantly increased in breast cancer patients when compared to controls. When the data on IM and PM were pooled, significant increase in the frequency of pooled genotype in disease group (42.4%) was observed as compared to controls (27.6%). The frequency of IM genotype was found to be increased in women with premenopausal breast cancer patients (43.5%) and patients with familial history of cancer (43.2%). Higher frequency of IM as well as pooled genotypes PM+IM was found in cases with higher BMI and in patients occupied in agriculture (55.6%), patients positive for estrogen receptor (47.8%), progesterone receptor (44.8%), HER2/neu (26.9%) and advanced stage. Our results suggested that the CYP2D6*4 polymorphism plays an important role in the breast cancer etiology and might help in planning hormonal therapy where tamoxifen is used.